COMP <GO>
TECH vs HALO // EV/EBITDA & P/E VALUATION
Bio-Techne Corp (NASDAQ) VS. Halozyme Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TECH 3
— HALO 10
▲ EV/EBITDA & P/E VALUATION LEADER: HALO
LAST: $72.66 (-0.07%) • MKT CAP: $11.39B
valuation
91.3x
LAST: $130.91 (-0.21%) • MKT CAP: $14.86B
valuation
35.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TECH VS. HALO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TECH | HALO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.80% | 83.60% | -18.80 | HALO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 18.00% | -14.60 | HALO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 91.3x | 35.6x | +55.70 | HALO | /valuation <GO> |
| Free Cash Flow Yield | 2.25% | 4.33% | -2.08 | HALO | /fcf-yield <GO> |
| Operating Margin | 8.40% | 33.60% | -25.20 | HALO | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 22.70% | -16.70 | HALO | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 37.60% | -32.40 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 0.00% | +0.44 | TECH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.12 | 5.11 | +2.01 | TECH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TECH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.1 | 77.8 | -21.70 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.88 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 39.5x | +100.50 | HALO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.39B | $14.86B | -$3.46B | HALO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TECH REV | HALO REV | TECH GROSS % | HALO GROSS % | TECH FCF | HALO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.22B | $1.40B | 64.8% | 83.6% | $256.6M | $644.6M |
| FY 2024 | $1.16B | $1.02B | 66.4% | 84.3% | $236.1M | $468.4M |
| FY 2023 | $1.14B | $829.3M | — | — | $203.2M | $351.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TECH // BETA 0.88
HALO // BETA 0.88